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Few studies have assessed the extent of psychoactive drug con-
sumption in the occupational setting. The trucking sector, in 
particular, is an important cause for concern, since psychoac-
tive substance use has a relevant impact on the drivers’ health 
and safety, increasing the risk of injuries and traffic accidents, 
potentially affecting the general public health as well. A system-
atic review of the literature and meta-analysis was performed in 
order to provide Occupational Health Professionals and policy-
makers with an updated epidemiological perspective regarding 
this important issue. The results showed a prevalence of overall 
drug consumption of 27.6% [95%CI 17.8-40.1], particularly high 
considering illicit CNS-stimulants (amphetamine consumption 
of 21.3% [95%CI 15.7-28.1], and cocaine consumption of 2.2% 
[95%CI 1.2-4.1]). It appears that truck-drivers choose stimulant 
substances as a form of performance enhancing drug, in order 
to increase productivity. However, chronic and high dose con-
sumption has been shown to decrease driving skills, placing these 
professional drivers at risk for health and road safety. Further 
research is required, particularly in Europe, in order to fill the 
knowledge gap and improve the strength of evidence.
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Introduction
Illicit drug and psychoactive substance misuse is an 
important contributor to the global burden of disease. 
According to data presented in the World Drug Review 
2018 published by the United Nations Office on Drugs 
and Crime (UNODC), 5.6% of the global population 
aged 15-64 years has used drugs in the previous year. 
Moreover, medical and non-medical prescription drug 
abuse, especially opioids, is reaching epidemic propor-
tions in many parts of the world [1].
These figures represent an increasing trend over the 
years, especially in developed countries. In its European 
Drug Report 2018, the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) has reported 
an annual prevalence of drug users equal to 7.4%, and 
drug-induced mortality surpassing 5 thousands deaths in 
EU countries [2]. Since working age population makes 
up most of the overall population, substance use among 
workers is of primary interest from an occupational per-
spective. Indeed, it can cause loss of productivity, work-
place injuries, absenteeism and increased illness [3]. 
Few international and national surveys using a system-
atic approach have studied drug use in the workplace: 
the Center for Behavioral Health Statistics and Qual-
ity (CBHSQ) report regarding substance use and sub-
stance use disorder by industry published by the Sub-
stance Abuse and Mental Health Services Administration 
(SAMHSA) reported an annual prevalence of illicit drug 
use of 9.5% among workers in the USA between the years 
2008-2012  [3]. In Europe, there is a lack of up-to-date 
and high quality epidemiological data about prevalence 
of drug use in the workplace. The trucking sector, in par-
ticular, is an important cause for concern: truck-drivers 
are a vulnerable working population due to a wide variety 
of hazards [4-6] including physical and ergonomic ones 
with the risk of developing musculoskeletal disorders [7], 
hypertension [8], obstructive sleep apnea (OSA) and sleep 
deprivation  [9, 10], exposure to diesel exhaust and risk 
of developing lung cancer [11]. Stressful conditions due 
to irregular working schedules, night shifts, being distant 
from families for long periods [12], the need for constant 
mental alertness, and high productivity demands  [13] 
increase risky behaviors such as smoking, drinking, us-
ing psychoactive substances, and having casual sexual 
contacts [14]. In particular, psychoactive drugs affect the 
functioning of the brain by delaying cognitive and execu-
tive functions, which may lead to impaired driving [15]. 
These can have a relevant impact on truck-drivers’ health, 
as well as on work safety, increasing the risk of injuries 
and traffic accidents [16, 17], often fatal: 21% of all lethal 
injuries occurred among “transportation and warehous-
ing” workers in Iowa in 2005-2009 had a positive toxicol-
ogy test for substance use [18]. Indeed, while the effects 
of ethanol on driving have been thoroughly studied by the 
literature, as shown in the previously published article by 
the Authors [19], the impact of other substances on driv-
ing is not as clear. The vast variety of substance classes, 
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each with specific effects on physical and mental health, 
requires a detailed understanding of the interaction and ef-
fect on work specific tasks. Italian law has identified sev-
eral occupational categories as at risk of harm to their and 
others’ health and safety, to which it prohibits drug use, 
even occasional  [20]. Nevertheless, not much is known 
regarding on site health surveillance and drug testing in 
this occupational sector.
A comprehensive analysis of this issue can adequately 
inform policy-makers in order to address legislative 
shortcomings and implement preventive measures in the 
workplace, reducing in turn the contribution of work-re-
lated drug health problems arising from working condi-
tions to the general public.
The aim of the present systematic review and meta-
analysis is to provide Occupational Health Profession-
als  and policy-makers with updated epidemiological 
data regarding drug consumption among truck-drivers, 
in order to reduce the knowledge gap, and in turn to al-
low the implementation of effective countermeasures 
taking place in the workplace. The reduction of drug-
related health problems induced by working condi-
tions will also beneficially contribute to public health. 
This study adds to the findings regarding alcohol con-
sumption in this occupational category, presented in our 
previously published article, and significantly updates 
and expands, through a rigorous quantitative analysis, 
the work performed by Girotto and colleagues [4].
Materials and methods
Systematic review
The current systematic review of the literature with me-
ta-analysis and meta-regressions is reported according to 
the Preferred Reporting Items for Systematic reviews and 
Meta-Analyses (PRISMA) guidelines  [21]. The study 
protocol was registered in the “International database 
of prospectively registered systematic reviews in health 
and social care” (PROSPERO database [22]; registration 
code CRD42016037077) [23]. The results of the study 
are reported in line with the PRISMA guidelines [24].
Briefly, a comprehensive pool of scholarly databases 
(namely, PubMed/MEDLINE (NLM), Scopus, SciVerse 
ScienceDirect, Science Citation Index Expanded (SCIE) 
and Social Sciences Citation Index from ISI/Web of Sci-
ence, ProQuest Research Library, ABI/INFORM, CB-
CA), via the UNO per TUTTI Primo Central (Ex Libris) 
platform) was searched from inception using the follow-
ing string of keywords: (truckers OR truck-drivers OR 
lorry OR commercial vehicles OR large good vehicles 
OR large vehicles OR heavy vehicles OR long vehicles 
OR trucking industry OR haul transport) AND (drugs 
OR psychostimulants OR psychoactive substances OR 
amphetamine OR benzodiazepines OR cocaine OR her-
oin OR opioids OR cannabis OR cannabinoids). Medi-
cal Subject Headings (MeSH) terms and wild-card op-
tion (truncated words) were used when necessary. Last 
search was carried out on 3rd December 2018. No lan-
guage restriction or time filter were applied. Gray litera-
ture was consulted via Google Scholar. Further details of 
the search strategy are reported in Table I. 
Literature search was performed by 2  researchers inde-
pendently (NLB and AR). In case of disagreement, con-
sensus was reached through discussion and consultation. 
Based on the PECO criteria, articles were included if: 
1) focused on truck-drivers (P = truck-drivers); 2) inves-
tigating drug consumption (E = exposure to abuse sub-
stances); 3)  stratifying according to parameters such as 
age, gender, marital status, experience years, mean dis-
tance travelled (per trip), work-load, night-shift or educa-
tional level, in terms of primary schooling level (C = any 
comparison); and 4)  reporting prevalence rate of drug 
consumption (O = drug consumption rate). Concerning 
the study design, articles were selected if devised as prev-
alence studies. Articles were excluded if not meeting with 
the above-stated PECO criteria and if designed as letter 
to editor, editorial, commentary, expert opinion, review 
article (of any type). 
Reviews were, anyways, scanned for reducing the 
chance of missing potentially relevant articles. Relevant 
information was extracted from each included article by 
two researchers independently (NLB and AR). In case 
of disagreement, a third researcher (GD) acted as final 
referee. For data extraction, an ad hoc Excel spreadsheet 
was designed and utilized. Besides tables, relevant infor-
mation was summarized by means of a narrative review. 
Methodological appraisal of studies quality 
Study quality was assessed utilizing the “Joanna Briggs In-
stitute Critical Appraisal tools for use in JBI Systematic Re-
views-Checklist for Prevalence Studies”. This tool explores 
different domains of quality: namely, 1) the appropriateness 
of the sample frame to address the target population; 2) the 
participants sampling technique; 3) the adequateness of the 
sample size; 4) the completeness of the description and de-
tails concerning the study subjects and the setting; 5) the 
coverage of the sample; 6) the validity of the methods; and 
7) their reliability; 8) the appropriateness of the statistical 
analyses; and, finally, 9) the adequateness of the response 
rate. Based on the JBI tool, studies were deemed of high, 
medium and low quality, respectively.
Meta-analysis 
For each outcome (amphetamine, benzodiazepines, canna-
bis, cocaine, heroin, opioid, OTC stimulants, overall drug 
consumption and poliabuse rates), effect size (ES) was 
computed pooling together the various prevalence rates, 
using the logit transformation approach.
Heterogeneity among studies was quantitatively assessed 
computing the I2 statistics. An amount greater than 50% 
was considered statistically significant [25, 26]. Based on 
the amount of heterogeneity, a fixed- or a random-effect 
model was chosen. 
Publication bias was studied both by visually inspecting the 
funnel plot in terms of asymmetry and by computing the 
Egger’s regression test [27] and the Duval and Tweedie’s 
trim-and-fill analysis [28]. Sensitivity analyses and cumu-
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lative meta-analyses were further performed, in order to 
verify the reliability and the consistency of the findings. 
All analyses were carried out with the commercial software 
Comprehensive Meta-Analysis (CMA version 3.0, for Win-
dows). 
For further details, the reader is referred to our previous 
publication [19].
Results
Systematic review 
The initial search resulted in a pool of 174,712 articles. 
After deleting duplicates, a set of 152,367  unique items 
was obtained. Screening titles and/or abstracts led to the 
exclusion of 153,132 items. A pool of articles was re-
trieved and accessed in full-text. Finally, 51 studies were 
included (Fig. 1). 
Investigations were carried out between 1983 and 2018. 
Sample sizes ranged from 30 to 11,242 subjects, with a 
total of 43,673 participants. 31 studies investigated drug 
consumption among truck-drivers utilizing question-
naires, whilst 14 and 6 studies utilized urine and saliva 
samples, respectively. 35 studies were performed in the 
Americas (1 in Canada, 6 in the USA, and 28 in Brazil), 
5 in Asia (3 in Thailand, 1 in Pakistan, and 1 in Iran), 
5 in Europe (3 in Italy, 1 in France and 1 in Norway), 
4 in Australia and 2 in Africa (1 in Morocco and 1 in 
Nigeria). 
Tab. I. Pooled drug consumption rates and respective ranges stratified according to the type of study (studies based on questionnaires, urine 
or saliva samples).
Drug
Drug consumption
Questionnaire Urine sample Saliva sample
Amphetamine 21.3% [95%CI 15.7-28.1] 3.8% [95%CI 1.7-8.2] 1.3% [95%CI 0.7-2.4]
Benzodiazepines 1.0% [95%CI 0.1-6.1] 0.4% [95%CI 0.2-0.6] NA
Cannabis 5.9% [95%CI 3.5-9.8] 2.1% [95%CI 1.0-4.3] 0.5% [95% 0.3-1.0%]
Cocaine 2.2% [95%CI 1.2-4.1] 1.1% [95%CI 0.7-2.0] 1.1% [95%CI 0.4-3.1]
Opioid 4.3% [95%CI 0.6-26.4] 2.0% [95%CI 0.6-6.6] NA
OTC stimulants 4.1% [95%CI 2.7-6.2] 9.0% [95%CI 4.3-18.0] NA
Overall drug consumption 27.6% [95%CI 17.8-40.1] 6.1% [95%CI 2.9-12.4] 4.1% [95%CI 1.2-13.1]
Poliabuse 2.7% [95%CI 0.2-25.6] 0.6% [95%CI 0.1-4.8] 0.3% [95%CI 0.1-0.7]
NA: not available; OTC: over-the-counter.
Fig. 1. PRISMA 2009, flow diagram. The process of retrieving and selecting articles adopted in the present systematic review and meta-
analysis.
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Age went from 33.5 to 43.85 years, with male percent-
age varying in the range 90.6-100.0%. Concerning the 
marital status, percentage of married subjects ranged 
from 62.0% to 94.9%. Percentage of truck-drivers 
with at least primary education varied between 35.2% 
and 100.0%, with schooling years going from 4.6 to 
8.7  years. Work-load ranged from 7.8 to 14.8 hours, 
with mean distance travelled varying between 270 km 
and 1,159.7 km. Percentage of truck-drivers working for 
companies was highly variable, in the range 0-76%. Ex-
perience years went from 10 to 18.5 hours. Finally, per-
centage of truck-drivers doing night-shifts ranged from 
10.7% to 33.0%. 
Concerning the outcomes, amphetamine consumption 
ranged from 0.0% to 82.5%, whereas cannabis and co-
caine use went from 0.0% to 29.9%, and from 0.1% to 
8.9%, respectively. Heroin consumption varied between 
0.1% and 0.9%. Opioid use ranged from 0.2% to 33.0%, 
while benzodiazepines consumption went from 0.0% to 
2.1%. OTC stimulant use ranged from 4% to 13%, while 
poliabuse prevalence was more variable (0.0-8.9%). Fi-
nally, overall drug use was in the range 1.3-80.4%.
Amphetamine consumption 
Based on questionnaires, the overall amphetamine con-
sumption rate was 21.3% ([95%CI 15.7-28.1], z = – 6.94, 
p < 0.0001, k = 22) (Supplementary Fig. 1A). Due to the 
high statistically significant heterogeneity (I2 = 97.15%), 
a random-effect model was applied (I2 = 64.91%). No 
evidence of publication bias could be found. At the meta-
regression analyses, significant moderators were found 
to be country (Q = 39.20, p < 0.0001, with the highest 
ES in Brazil, and the lowest ES in Nigeria) (Supplemen-
tary Fig. 2), age (coefficient = – 0.24, SE = 0.06 [95%CI 
– 0.36 to – 0.12], z = – 3.82, p = 0.0001) (Supplementary 
Fig. 3), marriage (coefficient = – 0.02, SE = 0.01 [95%CI 
–  0.04 to 0.00], z  =  –  1.99, p  =  0.0470), experience 
years (coefficient = – 0.34, SE = 0.10 [95%CI – 0.54 to 
– 0.14], z = – 3.37, p = 0.0008) (Supplementary Fig. 4), 
working for companies (coefficient = – 0.04, SE = 0.01 
[95%CI – 0.06 to – 0.01], z = – 2.72, p = 0.0065) and 
primary schooling level (coefficient = – 0.02, SE = 0.01 
[95%CI – 0.03 to – 0.01], z = – 2.69, p = 0.0071). Male 
(p = 0.1040), mean distance (p = 0.7928) and work-load 
(p = 0.3804) were not statistically significant. For the 
other moderators, meta-regression analyses could not be 
run due to insufficient number of studies. 
Based on studies utilizing urine samples, the overall 
amphetamine consumption rate was 3.8% ([95%CI 1.7-
8.2], z = – 7.70, p < 0.0001, k = 13) (Supplementary 
Fig. 5A). Due to the high statistically significant hetero-
geneity (I2 = 97.36%), a random-effect model was car-
ried out (I2 = 42.38%). No evidence of publication bias 
could be detected. At the meta-regression analyses, only 
country (Q = 23.64, p < 0.0001, with the highest ES in 
Thailand and the lowest ES in France) resulted a sta-
tistically significant moderator. Age (p = 0.1673), male 
(p = 0.0511) were not statistically significant modera-
tors. For the other moderators, meta-regression analyses 
could not be run due to insufficient number of studies. 
Based on studies utilizing saliva samples, the overall 
amphetamine consumption rate was 1.3% ([95%CI 0.7-
2.4], z = – 13.63, p < 0.0001, k = 5) (Supplementary 
Fig.  6A). Due to the high statistically significant het-
erogeneity (I2  =  83.68%) a random-effect model was 
applied (I2 = 47.67%). No evidence of publication bias 
could be found. For all the moderators, meta-regression 
analyses could not be run due to insufficient number of 
studies. 
Cannabis consumption 
Based on questionnaires, the overall cannabis consumption 
rate was 5.9% ([95%CI 3.5-9.8], z = – 9.88, p < 0.0001, 
k = 10) (Supplementary Fig. 1B). Due to the high statisti-
cally significant heterogeneity, (I2 = 96.81%), a random-
effect model was carried out (I2 = 62.28%). No evidence 
of publication bias could be found. At the meta-regression 
analyses, a significant moderator was found to be only 
country (Q = 15.85, p = 0.0146, with the highest ES in 
Pakistan, and the lowest ES in Iran). Age (p = 0.1044), 
male (p = 0.5799), marriage (p = 0.5939), mean distance 
(p  =  0.4235), experience years (p  =  0.7688), working 
for companies (p = 0.2192), and primary schooling level 
(p = 0.3200) were not statistically significant. For the other 
moderators, meta-regression analyses could not be run due 
to insufficient number of studies. 
Based on studies utilizing urine samples, the overall 
cannabis consumption rate was 2.1% ([95%CI 1.0-
4.3], z  =  –  9.97, p  <  0.0001, k  =  11) (Supplementary 
Fig. 5B). Due to the high statistically significant hetero-
geneity (I2 = 97.62%), a random-effect model was cho-
sen (I2  =  4.52). At the meta-regression analyses, only 
age (coefficient = – 0.50, SE = 0.09 [95%CI – 0.68 to 
– 0.33], z = – 5.56, p < 0.0001) resulted a statistically sig-
nificant moderator. Country (Q = 3.97, p = 0.5537), male 
(p = 0.2427) were not statistically significant moderators. 
For the other moderators, meta-regression analyses could 
not be run due to insufficient number of studies. 
Based on studies utilizing saliva samples, the overall 
cannabis consumption rate resulted 0.5% ([95% 0.3-
1.0%], z = – 15.69, p < 0.0001, k = 4) (Supplementary 
Fig. 6B). Due to the high statistically significant hetero-
geneity (I2 = 68.12%), a random-effect model was ap-
plied (I2 = 0.00%). The visual inspection of the funnel 
plot showed evidence of publication bias. At the Duval 
and Tweedie’s trim-and-fill analysis, 2 studies were cen-
sored, resulting in a “real” ES of 0.3% ([95%CI 0.1-0.7], 
Q = 33.21) (Supplementary Fig. 7). For all the modera-
tors, meta-regression analyses could not be run due to 
insufficient number of studies. 
Cocaine consumption 
Based on questionnaires, the overall cocaine consump-
tion rate was 2.2% ([95%CI 1.2-4.1], z  =  –  11.75, 
p < 0.0001, k = 9) (Supplementary Fig. 1C). Due to the 
high statistically significant heterogeneity (I2 = 91.66%), 
a random-effect model was applied (I2 = 50.78%). No 
evidence of publication bias could be found. Coun-
try (Q  =  6.06, p  =  0.1951), age (p  =  0.2460), male 
(p  =  0.2433), marriage (p  =  0.0541), mean distance 
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(p = 0.8952), experience years (p = 0.2604), working 
for companies (p  =  0.3851), primary schooling level 
(p = 0.5713) were not statistically significant modera-
tors. For the other moderators, meta-regression analyses 
could not be run due to insufficient number of studies. 
Based on studies utilizing urine samples, the over-
all cocaine consumption rate was 1.1% ([95%CI 0.7-
2.0], z = – 15.59, p < 0.0001, k = 10) (Supplementary 
Fig. 5C). Due to the high statistically significant hetero-
geneity (I2 = 88.74%), a random-effect model was car-
ried out (I2 = 19.33%). No evidence of bias was found. 
At the meta-regression analyses, no statistically sig-
nificant moderators could be found. Country (Q = 6.47, 
p = 0.1668), age (p = 0.5273), male (p = 0.3568) were 
not statistically significant moderators. For the other 
moderators, meta-regression analyses could not be run 
due to insufficient number of studies. 
Based on studies utilizing saliva samples, the overall co-
caine consumption rate resulted 1.1% ([95%CI 0.4-3.1], 
z = – 8.29, p < 0.0001, k = 3) (Supplementary Fig. 6C). 
Due to the high statistically significant heterogene-
ity (I2 =  88.18%), a random-effect model was chosen 
(I2 = 0.00%). No evidence of bias publication could be 
found. 
Opioid consumption 
Based on questionnaires, the overall opioid consumption 
rate was 4.3% ([95%CI 0.6-26.4], z = – 2.92, p = 0.003, 
k = 4) (Supplementary Fig. 1D). Due to the high statisti-
cally significant heterogeneity (I2 = 98.12%), a random-
effect model was performed (I2 = 0.00%). No evidence 
of publication bias could be found. At the meta-regres-
sion analyses, only age (coefficient = – 0.49, SE = 0.13 
[95%CI – 0.75 to – 0.23], z = – 3.70, p = 0.0002) re-
sulted a statistically significant moderator. For the other 
moderators, meta-regression analyses could not be run 
due to insufficient number of studies. 
Based on studies utilizing urine samples, the overall 
opioid consumption rate was 2.0% ([95%CI 0.6-6.6], 
z = – 6.13, p < 0.0001, k = 4) (Supplementary Fig. 5D). 
Due to the high statistically significant heterogene-
ity (I2 =  95.97%), a random-effect model was chosen 
(I2 = 0.00%). No evidence of publication bias was found. 
It was not possible to compute meta-regressions due to 
insufficient number of studies/missing information. 
Benzodiazepines consumption 
Based on questionnaires, the overall benzodiazepines 
consumption rate was 1.0% ([95%CI 0.1-6.1], z = – 4.81, 
p < 0.0001, k = 2). Due to the high statistically signifi-
cant heterogeneity (I2 = 70.57%), a random-effect mod-
el was carried out (I2 = 0.00%). Since there were only 
2  studies, it was not possible to conduct a publication 
bias analysis and meta-regressions.
Based on studies utilizing urine samples, the overall 
benzodiazepines consumption rate was 0.4% [95%CI 
0.2-0.6], z = – 21.71, p < 0.0001, k = 4). Due to the ab-
sence of heterogeneity (I2 = 0.00%), a fixed-effect model 
was applied. There was no evidence of publication bias. 
For all the moderators, meta-regression analyses could 
not be run due to insufficient number of studies. 
Over-the-counter stimulant consumption 
Based on questionnaires, the overall OTC stimulant con-
sumption rate was 4.1% ([95%CI 2.7-6.2], z = – 14.09, 
p < 0.0001, k = 3). Due to the high statistically signifi-
cant heterogeneity (I2 = 76.18%), a random-effect model 
was conducted (I2 = 28.35%). The visual inspection of 
the funnel plot gave evidence of publication bias. At the 
Duval and Tweedie’s trim-and-fill analysis, one study 
was censored, with a “real” ES of 3.5% ([95%CI 2.3-
5.3], Q = 15.46) (Supplementary Fig. 8). For all modera-
tors, meta-regression analyses could not be run due to 
insufficient number of studies. 
Based on studies utilizing urine samples, the overall 
OTC stimulant consumption rate was 9.0% ([95%CI 
4.3-18.0], k = 2). Due to the high statistically significant 
heterogeneity (I2 = 92.41%), a random-effect model was 
chosen (I2 = 0.00%). Since there were only 2 studies, it 
was not possible to conduct a publication bias analysis 
and meta-regressions. 
Poliabuse rate 
Based on questionnaires, the overall poliabuse rate was 
2.7% ([95%CI 0.2-25.6], z = – 2.80, p = 0.005, k = 2). 
Due to the high statistically significant heterogene-
ity (I2 = 96.14%), a random-effect model was applied 
(I2 = 0.00%). Since there were only 2 studies, it was not 
possible to conduct a publication bias analysis and meta-
regressions. 
Based on studies utilizing urine samples, the overall 
poliabuse rate was 0.6% ([95%CI 0.1-4.8], z = – 4.77, 
k = 5). Due to the high statistically significant heteroge-
neity (I2 = 90.76%), a random-effect model was carried 
out (I2 = 0.00%). No evidence of publication bias could 
be found. At the meta-regression analyses, only coun-
try (Q = 17.45, p = 0.0002, with the highest ES in the 
USA and the lowest ES in Italy) resulted a statistically 
significant moderator. For the other moderators, meta-
regression analyses could not be run due to insufficient 
number of studies.
Based on studies utilizing saliva samples, the overall 
poliabuse rate was 0.3% ([95%CI 0.1-0.7], z = – 12.98, 
p < 0.0001, k = 3). Due to the statistically significant 
heterogeneity (I2 = 61.68%), a random-effect model was 
performed (I2 = 0.00%). No evidence of publication bi-
as could be found. For all moderators, meta-regression 
analyses could not be conducted due to insufficient num-
ber of studies. 
Overall drug consumption
Based on questionnaires, the pooled overall drug con-
sumption rate was 27.6% ([95%CI 17.8-40.1], z = – 3.36, 
p = 0.001, k = 14) (Supplementary Fig. 1E). Due to the 
high statistically significant heterogeneity (I2 = 99.04%), 
a random-effect model was applied (I2 = 21.28%). There 
was no evidence of publication bias. At the meta-regres-
sion analyses, only age (coefficient = – 0.22, SE = 0.07 
[95%CI – 0.36 to – 0.08], z = – 3.13, p = 0.0018) result-
ed a statistically significant moderator. On the contrary, 
country (Q = 1.47, p = 0.8326), male (p = 0.9460), mar-
riage (p = 0.3583), mean distance (p = 0.9759), experi-
ence years (p = 0.1128), work-load (p = 0.9902), working 
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for companies (p = 0.8486), and primary schooling level 
(p = 0.3112) were not statistically significant modera-
tors. For the other moderators, meta-regression analyses 
could not be run due to insufficient number of studies. 
Based on studies utilizing urine samples, the pooled 
overall drug consumption rate was 6.1% ([95%CI 2.9-
12.4], p  <  0.0001, k  =  8) (Supplementary Fig.  5E). 
Due to the high statistically significant heterogeneity 
(I2 = 98.44%), a random-effect model was conducted 
(I2 = 0.00%). The visual inspection of the funnel plot 
showed evidence of publication bias. At the Duval 
and Tweedie’s trim-and-fill analysis, 1 study was cen-
sored, resulting in a “real” ES of 5.1% ([95% 2.4-10.1], 
Q = 543.42) (Supplementary Fig. 9). At the meta-regres-
sion analyses, only age (coefficient = – 0.36, SE = 0.09 
[95%CI – 0.53 to – 0.19], z = – 4.13, p < 0.0001) re-
sulted a statistically significant moderator. Country 
(Q = 1.65, p = 8003), and male (p = 0.8430) were not 
statistically significant moderators. For the other mod-
erators, meta-regression analyses could not be run due 
to insufficient number of studies. 
Based on studies utilizing saliva samples, the pooled 
overall drug consumption rate was 4.1% ([95%CI 1.2-
13.1], z = – 4.90, p < 0.0001, k = 5) (Supplementary 
Fig.  6D). Due to the high statistically significant het-
erogeneity (I2 =  98.89%), a random-effect model was 
conducted (I2 = 0.00%). For all the moderators, meta-
regression analyses could not be run due to insufficient 
number of studies.
Pooled drug consumption rates stratified according to 
the type of study are summarized in Table I.
Study quality
Findings of the critical appraisal of included studies are 
shown in Table II.
Discussion
To the best of our knowledge, this is the first systematic 
review with meta-analysis and meta-regressions on drug 
consumption rate among truck-drivers. Considering the 
meta-analysis performed on data extracted from ques-
tionnaires, the findings show an increased prevalence of 
drug use among truck-drivers, especially central nervous 
system (CNS) stimulants, compared to the general popu-
lation. In particular, the overall annual prevalence of am-
phetamine use among truck-drivers of 21.3%, compared 
to the estimated global prevalence of consumption in the 
general population of 0.7% [1], shows an almost 30-fold 
higher rate. 
Similarly, but to a lesser degree, the results regarding 
cocaine use showed a higher prevalence (2.2%) com-
pared to the general population (0.37%) [1]. In previous 
studies, stimulant consumption among truck-drivers has 
been associated with night shifts, length of travel and 
younger age [17, 75, 76]. Other authors have suggested 
that also external factors play a role, such as productiv-
ity-based payments [73]. In the present analysis, being 
younger and having less professional experience showed 
the most significant correlations with stimulant use. 
Drivers often take stimulants as a form of Performance En-
hancing Drugs (PEDs), in order to sustain ever increasing 
work-loads and busy work schedules. Several studies per-
formed in controlled clinical settings have suggested that 
low dose amphetamines could improve psychomotor skills, 
such as driving ability, even in fatigued subjects [77]. How-
ever, chronic and high dose users, taken in real life settings, 
showed poorer compliance with traf"c rules and working 
hours regulations [78], with an increased risk of traffic acci-
dents [79], mainly as a consequence of after effects such as 
hypersomnolence and fatigue [80, 81]. Some authors have 
suggested that blood concentration above 0.27-0.53 mg/l 
is associated with psychomotor impairment  [79]. Similar 
considerations have been made regarding cocaine use and 
its effects on psychomotor skills  [82-85]. Amphetamine 
use has been estimated to increase the risk of fatal accidents 
by 5-times, causing in 2013 around half of all road traffic 
deaths caused by illicit drug consumption worldwide, re-
sulting in around 20 thousand deaths [15]. 
The European Agency for Safety and Health at Work (EU-
OSHA) has acknowledged the spread and normalization 
Tab. II. Critical appraisal of studies included in the present systematic review and meta-analysis.
Study Domain I Domain II Domain III Domain IV Domain V Domain VI Domain VII Domain VIII Domain IX
Bombana et al. 
2017 [29] Yes No Yes Yes Yes Yes Yes Yes Yes
Cerqueira et al. 
2011 [30] Yes No No Yes Yes Yes Yes Yes Yes
Couper et al. 
2002 [31] No Yes Yes Yes Yes Yes Yes Yes Yes
De Oliveira et al. 
2015 [32] Yes No Yes Yes Yes Yes Yes Yes Yes
De Oliveira et al. 
2016 [33] Yes No Yes Yes Yes Yes Yes Yes Yes
Drummer et al. 
2007 [34] No Yes Yes Yes Yes Yes Yes Yes Yes
Girotto et al.
2015 [17] Yes No Yes Yes Yes Yes Yes Yes Yes
Gjerde et al.
2012 [35] No Yes Yes Yes Yes Yes Yes Yes Yes
Gjerde et al.
2014 [36] No Yes Yes Yes Yes Yes Yes Yes Yes
continues
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Tab. II. follows.
Study Domain I Domain II Domain III Domain IV Domain V Domain VI Domain VII Domain VIII Domain IX
Guinn et al.
1983 [37] No No No No Yes No No Yes Yes
Ingsathit et al. 
2009 [38] No Yes Yes Yes Yes Yes Yes Yes Yes
Knauth et al. 
2011 [39] Yes No Yes No Yes No No Yes Yes
Korelitz et al. 
1993 [16] Yes No Yes No Yes Yes Yes Yes Yes
Labat et al.
2008 [40] Yes Yes Yes Yes Yes Yes Yes Yes Yes
Laraqui et al.
2011 [41] Yes No Yes Yes Yes No No Yes Yes
Lemire et al.
2002 [42] No Yes Yes No Yes Yes Yes Yes Yes
Leopoldo et al. 
2015 [43] Yes No Yes Yes Yes Yes Yes Yes Yes
Leyton et al. 
2012 [44] Yes Yes Yes Yes Yes Yes Yes Yes Yes
Lund et al.
1988 [45] Yes Yes Yes Yes Yes Yes Yes Yes Yes
Maarefvand et al.
2016 [46] Yes No Yes Yes Yes Yes Yes Yes Yes
Mabbott and 
Hartley 1999 [47] Yes No Yes Yes Yes Yes Yes Yes No
Mansur Ade et al. 
2015 [48] No Yes Yes No Yes Yes Yes Yes Yes
Masson, Monteiro 
2010 [49] Yes
No No Yes Yes No No Yes Yes
Mieczkowski
2010 [50] No Yes Yes Yes No Yes Yes Yes Yes
Mir et al.
2012 [51] Yes Yes Yes No Yes No No Yes Yes
Mongkolsirichaikul 
et al. 1988 [52] Yes Yes No Yes Yes Yes Yes Yes Yes
Moreira, Gadani 
2009 [53] No No No No Yes No No Yes Yes
Nascimento et al. 
2007 [54] Yes No No No Yes No No Yes Yes
Okpataku
2016 [55] Yes Yes Yes Yes Yes Yes Yes Yes Yes
Peixe et al.
2014 [56] Yes No No Yes Yes Yes Yes Yes No
Penteado et al. 
2008 [57] Yes No Yes Yes Yes No No Yes Yes
Pereira et al.
2014 [58] Yes No No Yes Yes No No Yes Yes
Pidetcha et al. 
1995 [59] No No No No Yes Yes Yes Yes Yes
Pinheiro et al. 
2015 [60] Yes No No Yes Yes No No Yes Yes
Pinho 
2005 [61] Yes No Yes Yes Yes Yes Yes Yes Yes
Remor et al. 
2015 [62] Yes No Yes Yes Yes No No Yes Yes
Riva et al. 
2010 [63] Yes No Yes Yes Yes No No Yes Yes
Riva et al. 
2018 [64] Yes No Yes Yes Yes No No Yes Yes
Sangaleti et al. 
2014 [65] Yes No Yes Yes Yes No No Yes Yes
Silva et al. 
2003 [66] No Yes Yes No Yes Yes Yes Yes Yes
continues
PSYCHOACTIVE DRUG CONSUMPTION AMONG TRUCK-DRIVERS:  
A SYSTEMATIC REVIEW OF THE LITERATURE WITH META-ANALYSIS AND META-REGRESSION
E131
of stimulant use among certain groups of workers, par-
ticularly transportation workers, shift workers, and work-
ers in high pressure, competitive or bullying work cul-
tures [86]. It highlighted the need to evaluate the potential 
effect of non-medical drug used as cognitive enhancers in 
the workplace, and to consider the work environment and 
the interaction between workers and their working condi-
tions as important factors in the use of PEDs. 
Opiates, opioids, and CNS depressants, such as can-
nabinoids and benzodiazepines, showed a lower preva-
lence in the study population, and a smaller difference 
compared to the prevalence in the general population. 
In particular regarding cannabinoid use, the relatively 
high prevalence shown (5.9%), with the highest rates ex-
tracted from North American and European studies, fol-
lows the overall increasing rate of recreational and medi-
cal use of this type of drug in the general population: 
while an estimated 3.9% of the global population has 
used cannabinoids in the previous year, in North Amer-
ica the prevalence was higher at 13% [1], reaching over 
14% in the European Union with an increasing trend of 
high-risk use, meaning consuming cannabinoids 20 or 
more days in the past month [2]. Many CNS depressant 
have been found to reduce lane control by increasing the 
standard deviation of lateral position (SDLP)  [87-93]. 
Cannabis has been shown to impair cognitive, particu-
larly affecting working memory and divided attention, 
and psychomotor performances, increasing the chance 
of road accidents  [94]: according to systematic review 
and meta-analysis performed by Asbridge and collabo-
rators, acute cannabis consumption among drivers dou-
bles the risk of crashes compared to non-user [95]. 
Authors have suggested that tetrahydrocannabinol (THC) 
impairs mainly lateral control of the vehicle, while not af-
fecting longitudinal control [96, 97]. Moreover, interaction 
between cannabis and alcohol has been shown to have an 
additive effect on driving performance [91, 94, 98, 99] caus-
ing an increased risk of road accidents [100]. Indeed, can-
nabinoids are estimated to cause one fifth of all road traffic 
deaths caused by illicit drug consumption [15]. The impor-
tance of cannabis use in the workplace may grow further 
as countries reform medicinal and recreational cannabinoid 
laws enabling an increase in the rate of consumption [101]. 
Concerning the results of opiate/opioid use among truck-
drivers, the present analysis shows a prevalence of 4.3%, 
significantly higher compared to the rate of persons who 
use opiates and persons who use prescription opioids for 
non-medical purposes among the general population equal 
to 0.7% worldwide [1], and 0.4% in Europe [2]. 
However, similarly to cannabis, data show that there is a 
growing trend in the use of prescription drugs such as opi-
oids and sedatives, for medical and non-medical reasons, 
reaching epidemic proportions in some Western countries. 
In particular, past-year users of opioids in North America 
have reached a prevalence of 4.2% [1], similar to the re-
sults found in the present study. Moreover, opioids cause 
most of the negative health impact of drug use, account-
ing for three quarters of deaths from drug use disorders in 
2015 [1]. Although the role of opiates and opioid use in 
impairing driving ability is still unclear [102-106], there 
is suggestive evidence that opioids can cause an increased 
risk of vehicle collisions [1, 107]. 
Although the consumption of benzodiazepine was not 
found to be as common among truck-drivers, it must not 
be underestimated, as there is ample evidence of their 
impairing effect on driving skills, particularly regarding 
long-term benzodiazepines  [108-110]. Moreover, non-
medical use of benzodiazepines is the most common 
type of misuse of prescription drugs in the world [1].
Concerning drug testing for recent use, the results obtained 
through saliva sampling showed generally lower rates than 
those found on urine. This might be explained by the fact 
that urine drug testing can detect consumption occurred 
days or weeks before the sampling, resulting in low speci-
ficity for recent substance use. Research has suggested 
that saliva sampling has a stronger correlation with blood 
concentrations compared to urine, being also easier and 
faster to analyze and less intrusive to drivers  [111-113]. 
However, there is a lack of conclusive evidence, with other 
authors considering urine testing as a more accurate meth-
od for identification of substance use and disorders in the 
workplace [114]. Based on the prevalence of overall drug 
use obtained through biological sampling, around 1 every 
20 workers was driving under the influence of drugs. It is 
Tab. II. follows.
Study Domain I Domain II Domain III Domain IV Domain V Domain VI Domain VII Domain VIII Domain IX
Sinagawa et al. 
2014 [67] Yes Yes Yes Yes Yes Yes Yes Yes Yes
Souza et al.
2005 [68] Yes No Yes Yes Yes No No Yes Yes
Starmer et al. 
1997 [69] No No Yes No Yes Yes Yes Yes Yes
Takitane et al. 
2012 [70] Yes Yes Yes Yes Yes Yes Yes Yes Yes
Teles et al.
2008 [71] Yes No Yes Yes Yes Yes Yes Yes Yes
Valway et al.
2009 [72] Yes No Yes Yes Yes Yes Yes Yes Yes
Williamson
2007 [73] Yes No Yes Yes Yes No No Yes Yes
Yonamine et al. 
2012 [74] Yes Yes Yes Yes Yes Yes Yes Yes Yes
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worth noting that the country of origin of the driver was an 
often found association with drug use. Indeed, considering 
the data obtained from the included studies, there appears 
to be a pattern of consumption of specific substances in 
different areas, such as prevalent stimulant use in South 
America, cannabis use in North America and Europe, and 
opioid use in parts of Asia, likely because of availability, as 
well as historic and cultural reasons. 
Overall, the findings of the present study, adding to the re-
sults of the previously published systematic review and me-
ta-analysis concerning at-risk drinking, show that substance 
use is widespread among truck-drivers globally, putting 
workers and the general public at an increased risk of harm. 
The EU Action Plan on Drugs 2017-2020 states that, in or-
der to reduce and prevent drug use, effective evidence-based 
prevention measures must take into consideration situational 
factors, including workplace conditions [115]. There is in-
deed an urgent necessity for updated epidemiological data 
and research studying effective Occupational Health Promo-
tion programs, particularly in Europe, required in order to 
make and enforce effective policies, putting in place coun-
termeasures such as regular worksite drug testing, which has 
been shown to deter drug use among workers [116], as well 
as assessing working conditions that facilitate drug consump-
tion, such as excessive workloads demanded by companies.
Strengths and limitations
The strengths of our study consist in its methodologi-
cal rigor, reproducibility and transparency. We depos-
ited a priori study protocol, which further corroborates 
our meta-analysis. However, despite its novelty and its 
methodological robustness, our study is not without lim-
itations, which should be properly acknowledged. 
The high statistically significant heterogeneity may affect 
the generalization of the findings and calls up for caution in 
their interpretation. For some outcomes, few studies were 
available. In some cases, such paucity limited the possibil-
ity of conducting a full extensive e series of analyses, in-
cluding publication bias analysis and meta-regressions.
Conclusions
The present systematic review of the literature with 
meta-analysis and meta-regressions showed a relevant 
drug consumption rate among truck-drivers. As such, 
this study has practical implications for Occupational 
Physicians dealing with the health and wellbeing of 
truck-drivers. In particular, it appears that truck-drivers 
choose mainly stimulant substances as a form of perfor-
mance enhancing drug, in order to increase productivity. 
However, chronic and high dose consumption has been 
shown to decrease driving skills, placing these profes-
sional drivers, as well as the general public, at risk. 
Current literature is lacking in updated and reliable epi-
demiological data, especially in Europe. Therefore, fur-
ther research in the field is urgently needed in order to 
provide Occupational Health Professionals with up-to-
date data, necessary for the implementation of preven-
tive programs and effective workplace measures. More-
over, this can be useful for decision and policy-makers in 
order to fill the gaps and shortcomings in the regulations. 
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Supplementary material
Supplementary Fig. 1. Forest plots of amphetamine (A), cannabis (B), cocaine (C), opioids (D) and overall drug (E) use prevalence based 
on questionnaires. 
Supplementary Fig. 2. Meta-regression analysis of amphetamine use prevalence based on questionnaire, conducted for country as pa-
rameter. 
Supplementary Fig. 3. Meta-regression analysis of amphetamine use prevalence based on questionnaire, conducted for age as parameter.
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Supplementary Fig. 4. Meta-regression analysis of amphetamine use prevalence based on questionnaire, conducted for experience (in 
years) as parameter. 
Supplementary Fig. 5. Forest plots of amphetamine (A), cannabis (B), cocaine (C), opioids (D) and overall drug (E) use prevalence based 
on urine samples.
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Supplementary Fig. 6. Forest plots of amphetamine (A), cannabis (B), cocaine (C) and overall drug (D) use prevalence based on saliva 
samples.
Supplementary Fig. 7. Funnel plot of cannabis use prevalence based on saliva samples. showing evidence of publication bias. In white 
observed effect sizes, in black imputed effect sizes. 
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Supplementary Fig. 9. Funnel plot of overall drug use prevalence based on urine samples, showing evidence of publication bias. In white 
observed effect sizes, in black imputed effect sizes.
Supplementary Fig. 8. Funnel plot of over-the-counter stimulant use prevalence based on questionnaire, showing evidence of publica-
tion bias. In white observed effect sizes, in black imputed effect sizes. 
